New drug combination shows promise for small cell lung cancer

Researchers at the Icahn School of Medicine at Mount Sinai have made a promising breakthrough in the treatment of small cell lung cancer (SCLC). Their study, published in Science Advances and titled “ATR Inhibition Activates Cancer Cell cGAS/STING-Interferon Signaling and Promotes Anti-Tumor Immunity in Small Cell Lung Cancer,” presents an exciting new approach that offers hope to patients with this challenging disease.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup